Evidence map›Paper›PMID 32718961›Full record

ArticleAntimicrobial agents and chemotherapy2020

Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.

Ying Sun, Xueyuan Liao, Zhigang Huang, Yaliu Xie, Yanbin Liu, Cuicui Ma, Boguang Jiang, Li Zhang, Yuhang Yan, Guobo Li and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ying Sun *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Xueyuan Liao *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Zhigang HuangWuXi AppTec Co. Ltd., Shanghai, China.
Yaliu XieDepartment of Otolaryngology, The Seventh People's Hospital of Chengdu, Chengdu, China.
Yanbin LiuInfectious Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Cuicui MaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Boguang JiangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Li ZhangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Yuhang YanKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
Guobo LiKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
Xingjun ChengState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Qi YinState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Charles Z DingWuXi AppTec Co. Ltd., Shanghai, China.
Liang ShenWuXi AppTec Co. Ltd., Shanghai, China.
Jian LiWuXi AppTec Co. Ltd., Shanghai, China.
Shuhui ChenWuXi AppTec Co. Ltd., Shanghai, China.
Yuquan WeiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China.
Zhenling WangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, China wangzhenling@scu.edu.cn xiaweiwei@scu.edu.cn.ORCID 0000-0003-0364-8948
Xiawei WeiLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China wangzhenling@scu.edu.cn xiaweiwei@scu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the antimicrobial activity of the novel monosulfactam 0073 against multidrug-resistant Gram-negative bacteria

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAnimalsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesEnterobacteriaceaeMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-Lactamases0073Gram-negative bacteriamechanisms of actionmonosulfactamsusceptibilityβ-lactamases

Identifiers

PMID32718961
PMCPMC7508604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.